Deltagen in Research Deal With Schering Institute, Introduces New Database

Feb 24, 2000

Premium

M

ENLO PARK, Calif.--Deltagen announced the signing of a DeltaSelect research agreement with Schering-Plough Research Institute to validate small molecule drug targets. Schering-Plough will provide target gene sequences to Deltagen, which will use its proprietary mammalian gene knockout and phenotypic analysis technologies to enable Schering-Plough to define each gene’s function in vivo. Financial terms of the agreement were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Main menu